SCHEMBL8247239

SCHEMBL8247239

N#Cc1ccc(Cn2c(N)nc3ccccc32)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOD1 Q9Y239 3/20 0.69
TNF P01375 2/20 0.69
NOD2 Q9HC29 2/20 0.69
CXCL8 P10145 2/20 0.69
SOS1 Q07889 1/20 0.69
KMT2A Q03164 1/20 0.63
DRD2 P14416 1/20 0.59
TBXA2R P21731 1/20 0.59
HTT P42858 2/20 0.56
CYP1A2 P05177 1/20 0.56
CYP2D6 P10635 1/20 0.56
ALOX5AP P20292 1/20 0.56
POLB P06746 3/20 0.53
USP2 O75604 1/20 0.53
TSHR P16473 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
CXCR4 P61073 1/20 0.53
KCNH2 Q12809 1/20 0.51
CFTR P13569 1/20 0.49
CSF1R P07333 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7165480 0.88 TNF (0.87) NOD1TNFNOD2CXCL8SOS1
SCHEMBL17819068 0.85 KMT2A (0.59) NOD1TNFNOD2CXCL8SOS1
SCHEMBL8483250 0.85 CYP11B1 (0.55) NOD1TNFNOD2CXCL8SOS1
SCHEMBL4092820 0.84 DRD2 (0.64) NOD1TNFNOD2CXCL8SOS1
SCHEMBL939417 0.83 TNF (0.79) NOD1TNFNOD2CXCL8SOS1
SCHEMBL7530572 0.82 TNF (0.72) NOD1TNFNOD2CXCL8SOS1
SCHEMBL7337702 0.82 NOD1 (1.00) NOD1TNFNOD2CXCL8SOS1
SCHEMBL9630558 0.81 TNF (0.75) NOD1TNFNOD2CXCL8SOS1
Hydrochloric Acid SCHEMBL11594488 0.79 TNF (0.73) NOD1TNFNOD2CXCL8SOS1
SCHEMBL5462900 0.79 POLB (0.50) NOD1TNFNOD2CXCL8SOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7956196-B2 the major cause of lower respiratory tract illness during infancy and childhood TIBOTEC PHARMACEUTICALS LTD. (IE) 2011-06-07 US disclosed
US-20080146564-A1 1,3-Dihydro-Benzimidazol-2-Ylidene Amines as Inhibitors of Respiratory Syncytial Virus Replication JANSSEN SCIENCES IRELAND UC (IE) 2008-06-19 US disclosed
WO-2006097534-A1 1,3-DIHYDRO-BENZIMIDAZOL-2-YLIDENE AMINES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION TIBOTEC PHARMACEUTICALS LTD (IE) 2006-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146564-A1 1,3-Dihydro-Benzimidazol-2-Ylidene Amines as Inhibitors of Respiratory Syncytial Virus Replication H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, RTF2 NOD1 241/4885TNF 4684/4885NOD2 2023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.